FDA Delivers Wave of New Approvals Across Neurology, Oncology, and Rare Diseases

AbbVie's once-daily Parkinson's pill Juvmo (tavapadon) just got FDA approval, offering a convenient new option for the 11 million people worldwide living with the disease. The drug works by mimicking dopamine and was acquired through AbbVie's $8.7 billion purchase of Cerevel Therapeutics in 2023. Common side effects include nausea, dizziness, and headache, with analysts expecting gradual uptake as Medicare coverage negotiations progress.

Refills

**Rare...